Aptose Biosciences (APTO) Competitors $3.32 -0.38 (-10.27%) As of 03/28/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock APTO vs. JATT, CYTH, FNCH, CRIS, CVM, CGTX, CLDI, INAB, SNTI, and BCABShould you be buying Aptose Biosciences stock or one of its competitors? The main competitors of Aptose Biosciences include JATT Acquisition (JATT), Cyclo Therapeutics (CYTH), Finch Therapeutics Group (FNCH), Curis (CRIS), CEL-SCI (CVM), Cognition Therapeutics (CGTX), Calidi Biotherapeutics (CLDI), IN8bio (INAB), Senti Biosciences (SNTI), and BioAtla (BCAB). These companies are all part of the "biological products, except diagnostic" industry. Aptose Biosciences vs. JATT Acquisition Cyclo Therapeutics Finch Therapeutics Group Curis CEL-SCI Cognition Therapeutics Calidi Biotherapeutics IN8bio Senti Biosciences BioAtla JATT Acquisition (NYSE:JATT) and Aptose Biosciences (NASDAQ:APTO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, community ranking, institutional ownership, media sentiment, dividends, valuation and profitability. Is JATT or APTO more profitable? JATT Acquisition's return on equity of -49.58% beat Aptose Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets JATT AcquisitionN/A -49.58% 2.84% Aptose Biosciences N/A -5,683.22%-300.44% Which has preferable earnings & valuation, JATT or APTO? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJATT AcquisitionN/AN/A$6.85MN/AN/AAptose BiosciencesN/AN/A-$51.21M-$89.19-0.04 Does the MarketBeat Community believe in JATT or APTO? Aptose Biosciences received 384 more outperform votes than JATT Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformJATT AcquisitionN/AN/AAptose BiosciencesOutperform Votes38462.24% Underperform Votes23337.76% Do analysts rate JATT or APTO? Aptose Biosciences has a consensus target price of $112.00, suggesting a potential upside of 3,273.49%. Given Aptose Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Aptose Biosciences is more favorable than JATT Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score JATT Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Aptose Biosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Do institutionals and insiders believe in JATT or APTO? 48.0% of JATT Acquisition shares are owned by institutional investors. Comparatively, 26.6% of Aptose Biosciences shares are owned by institutional investors. 20.0% of JATT Acquisition shares are owned by company insiders. Comparatively, 1.3% of Aptose Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media favor JATT or APTO? In the previous week, Aptose Biosciences had 11 more articles in the media than JATT Acquisition. MarketBeat recorded 11 mentions for Aptose Biosciences and 0 mentions for JATT Acquisition. Aptose Biosciences' average media sentiment score of 0.45 beat JATT Acquisition's score of 0.00 indicating that Aptose Biosciences is being referred to more favorably in the news media. Company Overall Sentiment JATT Acquisition Neutral Aptose Biosciences Neutral SummaryAptose Biosciences beats JATT Acquisition on 7 of the 12 factors compared between the two stocks. Remove Ads Get Aptose Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for APTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APTO vs. The Competition Export to ExcelMetricAptose BiosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.11M$3.03B$5.63B$7.84BDividend YieldN/A1.55%5.33%4.01%P/E Ratio-1.1229.4223.5118.72Price / SalesN/A431.51388.1990.75Price / CashN/A168.6838.1734.64Price / Book-17.473.926.894.23Net Income-$51.21M-$71.95M$3.20B$247.47M7 Day Performance-10.03%-5.68%-3.06%-2.29%1 Month Performance4.08%-12.09%1.51%-5.81%1 Year Performance-93.33%-27.90%9.35%-0.94% Aptose Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APTOAptose Biosciences2.2422 of 5 stars$3.32-10.3%$112.00+3,273.5%-93.3%$7.11MN/A-1.1231Upcoming EarningsAnalyst ForecastShort Interest ↓News CoverageGap DownJATTJATT AcquisitionN/A$1.39-0.7%N/A-50.8%$23.98MN/A0.003High Trading VolumeCYTHCyclo Therapeutics2.8602 of 5 stars$0.71+1.5%$0.95+33.7%N/A$23.40M$870,725.00-0.799Upcoming EarningsShort Interest ↓FNCHFinch Therapeutics GroupN/A$14.00+2.2%N/A+440.6%$22.48M$110,000.00-1.59190News CoverageCRISCuris2.692 of 5 stars$2.60-2.3%$23.00+784.6%-78.7%$22.01M$10.26M-0.3360Upcoming EarningsAnalyst ForecastNews CoverageCVMCEL-SCIN/A$0.27+2.4%N/A-87.5%$20.56MN/A-0.5543Analyst ForecastHigh Trading VolumeCGTXCognition Therapeutics3.7346 of 5 stars$0.49+7.7%$7.50+1,431.2%-77.2%$20.35MN/A-0.5020Short Interest ↓Analyst RevisionCLDICalidi Biotherapeutics2.1934 of 5 stars$0.73-1.9%$15.00+1,966.4%N/A$19.21M$50,000.000.0038News CoverageGap DownINABIN8bio3.0307 of 5 stars$0.23-2.1%$6.00+2,532.7%-83.4%$18.52MN/A-0.3020Short Interest ↑Gap UpSNTISenti Biosciences3.6871 of 5 stars$3.72+1.1%$10.00+168.8%-9.0%$17.97M$2.56M-0.244Short Interest ↓Positive NewsGap UpBCABBioAtla2.3302 of 5 stars$0.37+5.4%$6.00+1,521.6%-89.1%$17.89M$11M-0.2260Earnings ReportShort Interest ↑News CoverageGap Down Remove Ads Related Companies and Tools Related Companies JATT Acquisition Competitors Cyclo Therapeutics Competitors Finch Therapeutics Group Competitors Curis Competitors CEL-SCI Competitors Cognition Therapeutics Competitors Calidi Biotherapeutics Competitors IN8bio Competitors Senti Biosciences Competitors BioAtla Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APTO) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHuge Elon-backed AI rollout begins – buy these nine stocksIf you suspect Elon Musk has an ulterior motive for coming to Washington, D.C.... You're 100% correct. ...Altimetry | SponsoredDoomed: These 50 Stocks Will Die Under Trump’s MAGA policies.Remember Kodak? Sears? Circuit City? They all failed to adapt to the changing times. Now, history is abo...Banyan Hill Publishing | SponsoredTrump… a socialist? Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptose Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptose Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy APTO Stock Free APTO Stock Alerts